People

Serves as Board Member at Paradigm Health, according to its current team directory.

RNA interference researcher at UMass Medical School and co-recipient of the 2006 Nobel Prize in Physiology or Medicine for the discovery of RNA interference.

Stanford biochemistry professor and former president of Merck Research Laboratories; named a Vaccine Company director in its 2024 filing.

Co-founder of Blitzscaling Ventures. The March2026 SEC filing lists Jeffrey Abbott as a manager of the AI fund’s general partner.

Venture partner at Blitzscaling Ventures working with Korean startups, co-investors and limited partners. Sogang graduate and Fulbright MBA who founded BoxLadder; distinct from the namesake Axiom/Elevate executive.

Augie Sick is listed by ONAMI as Entrepreneur-in-Residence. The organization's own named staff biography establishes this affiliation.

Juanita Kurtin is listed by ONAMI as Entrepreneur-in-Residence. The organization's own named staff biography establishes this affiliation.

Shula Jaron is listed by ONAMI as Entrepreneur-in-Residence. The organization's own named staff biography establishes this affiliation.

John Brewer Jr is listed by ONAMI as Entrepreneur-in-Residence. The organization's own named staff biography establishes this affiliation.

Eileen Brewer is listed by ONAMI as Digital Media Creator. The organization's own named staff biography establishes this affiliation.

Danielle Clair is listed by ONAMI as Vice President, Operations. The organization's own named staff biography establishes this affiliation.

Skip Rung is listed by ONAMI as Chief Startup Officer and President. The organization's own named staff biography establishes this affiliation. His full name is Robert D. Rung; the official directory uses the familiar name Skip.

Jay Lindquist is listed by ONAMI as Executive Director. The organization's own named staff biography establishes this affiliation.

Camille Guers-Renz appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Isaac Patchen appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Ella Hiebert appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Emi Eckhaus appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Trevor Linnell appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Roman Shusterman is identified as Chief Technology Officer of Brain Electrophysiology Laboratory Company in the FDA's April 10, 2025 NEAT 001 clearance letter. BEL's research and workflow software talks also use the name Roma Shusterman. The FDA role is documented as of that filing; a newer company management roster has not been established.

Chief scientific officer for translational biology at ChronicleBio, with experience in immunology and drug development.

Head of platform and founding scientist at ChronicleBio, working on computational biology and longitudinal human biological data.

Co-founder and executive chairman of ChronicleBio.

Co-founder and director of ChronicleBio, supporting its work on therapies for complex chronic disease.

Co-founder and CEO of ChronicleBio, with a background in biobanking and precision medicine at Stanford and UCSF.

Georgia Needham is listed by Caravel Bio as Biotechnologist. The company's current team directory is the source for this role and original individual portrait.

Arushi Kalia is listed by Caravel Bio as Senior Engineering Research Associate. The company's current team directory is the source for this role and original individual portrait.

Aidan Haney is listed by Caravel Bio as Biotechnology Engineer I. The company's current team directory is the source for this role and original individual portrait.

Dana Merrick is listed by Caravel Bio as Founding Infrastructure Engineer. The company's current team directory is the source for this role and original individual portrait.

Rick Sayler is listed by Caravel Bio as Head of BioInorganic Engineering. The company's current team directory is the source for this role and original individual portrait.

Agneya Bhushan is listed by Caravel Bio as CINO. The company's current team directory is the source for this role and original individual portrait.

Michał Jastrzębski is listed by Caravel Bio as CTO. The company's current team directory is the source for this role and original individual portrait.

Emily Bowman is listed by Caravel Bio as CSO. The company's current team directory is the source for this role and original individual portrait.

Trevor Nicks is listed by Caravel Bio as FOUNDER & CEO. The company's current team directory is the source for this role and original individual portrait.

Allison C. Waters is a neuroscience researcher at the Icahn School of Medicine at Mount Sinai and is explicitly identified by Neurosom as a Medical Advisor in its announcement of a second Parkinson's disease study using Sleep WISP. Her university research collaboration is distinct from the documented company advisory role.

Tess Pablo Teittinen is listed by Neurosom as Accounting Manager. The current company management directory and original named portrait establish this role. Historical image filenames are not used to infer a different present title.

Corin Tucker is listed by Neurosom as Chief Marketing Officer. The current company management directory and original named portrait establish this role. Historical image filenames are not used to infer a different present title.

Dee Dee Nunes is listed by Neurosom as Commercial Leader. The current company management directory and original named portrait establish this role. Historical image filenames are not used to infer a different present title.

Phan Luu is Chief Science Officer of Brain Electrophysiology Laboratory Company (BEL) and Chief Technology Officer of affiliate Neurosom. He develops dense-array EEG and transcranial electrical stimulation technologies and previously held scientific and technical leadership roles at Electrical Geodesics and EGI Philips Neuro.

Don Tucker is founder and CEO of Brain Electrophysiology Laboratory Company (BEL), founded in 2018, and Chairman and Chief Science Officer of affiliate Neurosom. Neurosom's SEC filing identifies him as Don M. Tucker. He founded Electrical Geodesics, Inc. in the early 1990s and is an emeritus University of Oregon psychology professor. The two affiliated companies publish distinct current role titles.

Viral Sheth is listed by Neurosom as CEO. The current company management directory and original named portrait establish this role. Historical image filenames are not used to infer a different present title.

Business lawyer and administrative board member at Brainlab. Partner at Argon Management and PMT Management, with earlier leadership roles at Swiss law firms.

Administrative board member at Brainlab. Former executive board member of the Federation of German Industries and a partner at FGS Global since April 2026.

Biotech entrepreneur and investor; co-founder of AYOXXA Biosystems and Proteona, and managing director of Springboard Health Ventures. Published as an EIC Fund portfolio-company board representative; ARTHEx Biotech independently names him as its EIC Fund board representative.

Chief product officer at Robeauté, working on medical microrobotics. Distinct from the namesake CEO of Previa Medical.

Co-founder and COO of Robeauté, leading operations for its neurosurgical microrobot development.

Co-founder and CEO of Robeauté. Robotics engineer and entrepreneur who previously founded Virtools, acquired by Dassault Systèmes.

Jim Huston co-founded Portland Seed Fund with Angela Jackson in 2011 and is currently listed as Managing Director Emeritus. His official biography describes earlier investment roles at Blueprint Ventures, Intel Capital and Exxon, and a focus on climate technology investing since 2022.

Shashi Jain is Venture Partner at Portland Seed Fund and Intrepid Oregon Fund, supporting early-stage deep technology businesses. His official biography describes earlier strategic innovation work at Intel involving IoT, healthcare, AI for space applications and blockchain, and community work in 3D printing and entrepreneurship.

Steve Eichenlaub is Managing Director of Portland Seed Fund IV and Intrepid Oregon Fund I. His official firm biography describes an association with Portland Seed Fund since 2014 as a limited partner in Funds II and III, and earlier executive and investing roles at M-SIX and Intel Capital.

Jenn Lynch is Managing Director of Portland Seed Fund, leading finance and investor relations. Her official biography identifies investing-partner roles with Funds II and III and an adviser role with Fund IV. She previously worked in software product management and Portland technology agencies.

Angela Jackson co-founded Portland Seed Fund in 2011 and is Managing Director of the firm and its deep-tech sister Intrepid Oregon Fund. Her official biography describes earlier roles at Portfolia, Emergent and Oregon's Angel Oregon program, and leadership of the Portland State Business Accelerator.

Tim Vogel is listed by Neurobiome as Partner. The company's own biography and original named portrait establish this affiliation; outside university positions are not assigned as company roles.

Maude David is listed by Neurobiome as Managing Partner. The company's own biography and original named portrait establish this affiliation; outside university positions are not assigned as company roles.

Kenton Hokanson is listed by Neurobiome as Partner. The company's own biography and original named portrait establish this affiliation; outside university positions are not assigned as company roles.

Zach Lerner is CTO and co-founder of Biomotum, developing assistive robotics for neurological mobility impairments. The current company directory identifies him as CTO; earlier investor and university materials use CSO. NIH awards identify Zachary Forest Lerner, while SEC filings use a different middle initial, so a longer legal name has not been inferred.

Ray Browning is CEO and co-founder of Biomotum, developing wearable robotic assistance for impaired walking. His current title and original portrait are published in the company's leadership directory.

Portfolio lead and managing director of Noctua Science Ventures. Previously supported TU Wien spinouts and co-founded Dataholics and HROS.

Life-sciences and healthcare investor at Obvious with prior Verily and Northpond experience; studied biological sciences at Oxford and earned an MBA at Harvard.

Heads autonomous AI at Synteny, working on systems for scientific exploration. His background includes UiPath, reinforcement learning, generative models and large language models.

Leads protein-engineering AI at Synteny, with a focus on artificial intelligence for drug discovery.

Heads discovery at Synteny. Previously led target identification and development work on Immunocore’s KIMMTRAK T-cell receptor therapy.

Heads computational biology at Synteny, following a research career at Microsoft Research in biological computation.

Co-founder and chief scientific officer of Synteny. Leads a research laboratory at Cambridge’s Early Cancer Institute studying quantitative cancer evolution.

Co-founder and CEO of Synteny. Previously co-headed Growth Equity at Generation Investment Management; studied computational biology at Cambridge and mathematics at Dartmouth.

Senior software engineer at Roofline. A different person from SHS Capital partner Tobias Fuchs, whose own biography and LinkedIn identity describe a finance and law career.

Kanth Gopalpur is listed by Elevate Capital as Advisor. The official firm biography is the source for this affiliation.

Stephen Marsh is listed by Elevate Capital as Advisor. The official firm biography is the source for this affiliation.

Barbara Johnson is listed by Elevate Capital as Executive Assistant. The official firm biography is the source for this affiliation.

Pam Gates is listed by Elevate Capital as Controller. The official firm biography is the source for this affiliation.

Raghu Raghavan is listed by Elevate Capital as Partner Emeritus. The official firm biography is the source for this affiliation.

Robin Jones is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Ketan Sampat is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Ana Chaud is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Randy Lund is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Chris Bright is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Michael Choi is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Jill Nelson is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Lateef Jackson is listed by Elevate Capital as Limited Partner. The official firm biography is the source for this affiliation.

Doug Fieldhouse is listed by Elevate Capital as Limited Partner. The official firm biography is the source for this affiliation.

Donn Dimond is listed by Elevate Capital as Limited Partner. The official firm biography is the source for this affiliation.

Tariq Q. Khan is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Supriya Rao is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Srivatsan Laxman is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Krishna Chittabathini is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Annu Navani is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Soumitra Sengupta is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Giovanni Magni is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Dipty Desai is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Anu Shukla is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Allie Persitz is listed by Elevate Capital as Operating Partner. The official firm biography is the source for this affiliation.

Brandon Ross is listed by Elevate Capital as Senior Associate-Analyst. The official firm biography is the source for this affiliation.

Vageesh Jha is listed by Elevate Capital as Associate (Fund Operations & Administration). The official firm biography is the source for this affiliation.

Ben Nahir is listed by Elevate Capital as Partner. The official firm biography is the source for this affiliation.

Kumar Sripadam is listed by Elevate Capital as General Partner. The official firm biography is the source for this affiliation.

Nitin Rai is listed by Elevate Capital as Founder & Managing Partner. The official firm biography is the source for this affiliation.

Kristy Lawton is the scientific lead of Rewire AI and a neuroscience researcher. In Rewire’s November 2021 company article, she identifies herself as Chief Science Officer; the Coffin Lab’s alumni directory identifies her as Chief Scientific Officer of Rewire AI. She is an inventor named on the company’s adaptive machine-learning technology. A verified individual portrait was not located.

John Harkness is the founder and CEO of Rewire AI, previously Rewire Neuro. He earned a behavioral-neuroscience doctorate at Oregon Health & Science University in 2015 and researched perineuronal nets at Washington State University Vancouver, where he developed Pipsqueak image-analysis software. His March 2025 legislative testimony confirms the founder and CEO role; older WSU materials describe an earlier co-founder and Chief Science Officer role.

Group Technical Director at Phoenix Sustainable Investments, overseeing technical strategy, due diligence, infrastructure planning and sustainable project delivery across the group. Joined the group in 2023.

Founder of Farang, a Swedish foundational AI research company. The company describes his background as engineering, search, artificial intelligence and startup ventures.

Kiutra lists Wolfgang Neubert in its Board and advisors directory as its APEX Ventures representative. The directory does not specify a separate director or adviser title.

Edward White is listed by Luminate NY as Advisory Board Member.

Marc Tricard is listed by Luminate NY as Advisory Board Member.

Linda Smith is listed by Luminate NY as Advisory Board Member.

Barry Silverstein is listed by Luminate NY as Advisory Board Member.

James Senall is listed by Luminate NY as Advisory Board Member.

Darius Sankey is listed by Luminate NY as Advisory Board Member.

Ryne P. Raffaelle is listed by Luminate NY as Advisory Board Member.

Duncan Moore is listed by Luminate NY as Advisory Board Member.

Michael Jackman is listed by Luminate NY as Advisory Board Member. Listed in Despierta’s combined advisors/select-LPs group, without an individual commitment or precise capacity. Its published biography describes Leidos healthcare operations and prior Ardan Equity, Mach7, GE Healthcare, Carestream and IBM work. These outside titles are undated source credentials, not newly asserted current positions.

David Heller is listed by Luminate NY as Advisory Board Member.

Don Golini is listed by Luminate NY as Chairman, Advisory Board.

Stephen D. Fantone is listed by Luminate NY as Advisory Board Member.

Stu Elby is listed by Luminate NY as Advisory Board Member.

Milton Chang is listed by Luminate NY as Advisory Board Member.

Jenifer Bunis is listed by Luminate NY as Advisory Board Member.

Thomas Brown is a Luminate advisory board member and director of the University of Rochester’s Institute of Optics. He is distinct from Anthropic co-founder Tom Brown.

Harsh Yallapragada is listed by Luminate NY as Data Analyst (shared NextCorps staff).

Morgan Adams is listed by Luminate NY as Marketing and Content Coordinator (shared NextCorps staff).

Kate Leonard is listed by Luminate NY as Digital Marketing Manager (shared NextCorps staff).

Anjali Boriya is listed by Luminate NY as Finance Analyst.

Natalie Antal is listed by Luminate NY as Director, Sponsored Programs.

Holly Barrett is listed by Luminate NY as Marketing (shared NextCorps Chief Marketing Officer).

Veronica LoCurcio is listed by Luminate NY as Director of Operations.

Damon Diehl is listed by Luminate NY as Director of Technology Integration.

Sujatha Ramanujan is the former Managing Director and Chief Investment Officer of Luminate NY. On October 6, 2026, the University of Rochester announced her appointment as CEO of the NSF STELLAR Engine and her planned move to Luminate’s advisory board.

Roshni Christo joined Neurescence in 2020 as a Field Application Scientist. Bruker’s post-acquisition researcher profile identifies her as Senior Application Scientist for Multi-Region Miniscope Microscopy at Bruker. Her earlier work includes neuroscience research at Baylor College of Medicine.

Taufik Valiante is a Neurescence co-founder identified in Google’s accelerator story, which describes his input into the company’s epilepsy research direction. He is a University Health Network neuroscience researcher; his current operating role at the acquired company is not established.

Sepideh Hashemi is a co-founder of Neurescence. Google’s founder story describes her joining Yasaman Soudagar in 2018, bringing medical-device development and commercialization experience. Her current operating role following the Bruker acquisition is not established.

Yasaman Soudagar is a Neurescence co-founder and its former CEO. A physicist trained in experimental quantum optics, she helped develop multi-region miniscopes. Bruker’s post-acquisition researcher profile identifies her as Senior Director of Multi-Region Miniscope R&D at Bruker.

Mark Schnitzer is a Stanford neuroscience and optical imaging researcher and scientific co-founder of Inscopix, established in 2011 to commercialize the miniature microscope developed at Stanford.

Abbas El Gamal is a Stanford electrical engineering researcher and co-founder of Inscopix, established in 2011 to commercialize the miniature microscope developed at Stanford.

Keh-Yi Hong is listed in Inscopix’s public directory as General Manager, Asia Pacific Commercial Operations. The directory includes historical entries; current employment has not been independently confirmed.

Shay Neufeld is listed in Inscopix’s public directory as Director, Data Products and Analytics. The directory includes historical entries; current employment has not been independently confirmed.

Shanna Resendez is listed in Inscopix’s public directory as Senior Director, Customer Excellence. The directory includes historical entries; current employment has not been independently confirmed.

Sarah MacNamee is listed in Inscopix’s public directory as Senior Director, Sales, Western Markets. The directory includes historical entries; current employment has not been independently confirmed.

Jonathan Nassi is listed in Inscopix’s public directory as Senior Director, Translational Science. The directory includes historical entries; current employment has not been independently confirmed.

Michaela Mueller is listed in Inscopix’s public directory as Chief Financial Officer. The directory includes historical entries; current employment has not been independently confirmed.

Kunal Ghosh founded Inscopix in 2011 to commercialize the Stanford miniscope. He served as CEO, continued to lead the business after its acquisition by Bruker in 2022, and has since announced his departure from Bruker.

Chemist and founder of AMADTEUS Technologies, working on multicomponent chemistry, automated nanoscale synthesis and drug discovery.

Organic chemist and chemical biologist; founder and Chief Scientific Officer of MendelFOLD. Holds Ph.D., FRSC and CChem credentials. Distinct from the neuroscience executive Andrew Miller, chair of Progentos Therapeutics.

Vijay Barathan is Optum Ventures global partner based in London. Previously he invested in digitalhealth and life sciences atCatapult, led healthcareIPcommercialisation investments and worked in healthcare investmentbanking atPeelHunt/PiperJaffray. He initially practisedNHSmedicine and trained atGuy’s,KingsandStThomas, with medical and developmental-neurobiology degrees. His existing XRHealth affiliation remains separate and preserved.

Isabel Jiménez Bernal is an investment professional at Asabys Partners, publicly promoted to Principal in2025. Augustine Therapeutics’ June2024 first SeriesA closing announcement named Isabel Jiménez of Asabys as a new board observer. Her full Asabys identity is corroborated by her own public promotion post and existing institutional affiliation; she is distinct from Isabel Jiménez at Biocross. The Augustine observer relationship is a dated appointment and does not establish a personal investment or current executive employment. Asabys’ current published biography confirms she is a Principal who joined in 2022, and currently serves as board observer at Augustine Therapeutics and Orikine Bio. She previously worked with Ysios Capital and in hemato-oncology and immunology at VHIO; she holds a medicine PhD from the Autonomous University of Barcelona, an immunology master’s and an ESADE Executive MBA.

Artificial intelligence researcher and advisory board member at MJN Neuro.

Clinical advisory board member of ProMIS Neurosciences and board observer at ADmit Therapeutics. Physician and co-founder of the Alzheimer’s Drug Discovery Foundation with expertise in dementia research and therapeutic development. Howard Fillit is Co-Founder and Chief Science Officer Emeritus at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Emeritus; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.